GPX4 and ovarian carcinoma: NRF2/GPX4 (RSL3) combinations in ovarian cancer and head and neck cancer (N. Li et al. 2024; Shin et al. 2018) and taxol in GPX4 inhibit the proliferation of cell lines (Feng et al. 2023).